A guide to neuromodulation in drug‐resistant epilepsy
Year: 2026
Type: article
Abstract: Neuromodulation is approved for the treatment of drug-resistant epilepsy. It has been increasingly utilized over the past two decades with the approval of deep brain stimulation (DBS) and responsive neurostimulation (RNS) in addition to vagus nerve stimulation (VNS)-particularly in patients who are not deemed to be good resective surgical candidates or in case of patient preference. In this seminar in epileptology article, we address learning objective 3.7 "Demonstrate knowledge of indications, limitations and risks for vagal nerve stimulation and other neuromodulation techniques" of the International League Against Epilepsy curriculum for epileptologists. We will review the indications for neuromodulation, device programming, surgical considerations for implantation, side effects, effects on sleep, and mood. This is complemented by case examples that provide perspective for trainees, along with an outlook on future directions for neuromodulation in epilepsy. This article aims to serve as a learning resource for trainees in neurology, clinical neurophysiology, and epileptology by providing guidance in how to navigate the landscape of neuromodulation in epilepsy.
Source: Epileptic Disorders
DOI: 10.1002/epd2.70221
Institutions: Duke Medical Center, Masaryk University, St. Anne's University Hospital Brno, University of California, San Francisco, Swiss Epilepsy Center, Mayo Clinic, Inserm, Aix-Marseille Université, Institut de Neurosciences des Systèmes, Hôpital de la Timone, The Ohio State University, Saitama Medical University Hospital, Saitama Medical University, Duke University
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,430
OpenAlex ID: W7140974441
